For the twelve months ended Jun 30, 2026, Protalix BioTherapeutics Inc. (DE) reported $80.62M of revenue and $18.95M of net income.
PLX revenue was $19.90M in fiscal Q2 2026 (ended Jun 30, 2026), up 27.1% from a year earlier and down 41.0% from the prior quarter. For the full fiscal 2025 it was $52.74M, down 1.2% from fiscal 2024. Compound annual growth was -3.5% over 5 years and +28.3% over 10 years. It rose in 7 of the last 10 fiscal years.
PLX net income was $3.78M in fiscal Q2 2026 (ended Jun 30, 2026), up about 23-fold from a year earlier and down 79.4% from the prior quarter. For the full fiscal 2025 it was -$6.60M, compared with $2.93M in fiscal 2024.
PLX diluted EPS was $0.05 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0.00 a year earlier and down 77.3% from the prior quarter. For the full fiscal 2025 it was -$0.08, compared with $0.04 in fiscal 2024.
PLX free cash flow was -$10.99M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.66M a year earlier. For the full fiscal 2025 it was -$13.63M, compared with $7.39M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.74M | $53.40M | $65.49M | $47.64M | $38.35M | $62.90M | $54.69M | $34.24M | $21.08M | $9.20M |
| Cost of revenue | $26.99M | $24.32M | $22.98M | $19.59M | $16.35M | $10.87M | $10.89M | $9.30M | $15.23M | $8.40M |
| Gross profit | $25.75M | $29.08M | $42.51M | $28.05M | $22.00M | $52.02M | $43.80M | $24.94M | $4.01M | $801.0K |
| Research and development | $19.57M | $12.97M | $17.09M | $29.35M | $29.73M | $38.17M | $44.62M | $33.33M | $32.17M | $30.41M |
| Selling, general and admin | $11.68M | $12.19M | $14.96M | $11.71M | $12.73M | $11.15M | $9.90M | $10.92M | $11.53M | $9.36M |
| Operating income | -$5.50M | $3.92M | $10.46M | -$13.01M | -$20.46M | $2.71M | -$10.72M | -$19.31M | -$34.52M | -$33.16M |
| Pre-tax income | -$5.61M | $4.15M | $8.57M | -$14.40M | -$27.58M | -$6.52M | - | - | - | - |
| Income tax | $996.0K | $1.22M | $254.0K | $530.0K | - | - | - | - | - | - |
| Net income | -$6.60M | $2.93M | $8.31M | -$14.93M | -$27.58M | -$6.52M | -$18.28M | -$26.46M | -$83.44M | -$29.36M |
| EPS, basic | -$0.08 | $0.04 | $0.12 | -$0.31 | -$0.62 | -$0.22 | -$1.23 | -$1.80 | -$6.37 | -$2.90 |
| EPS, diluted | -$0.08 | $0.04 | $0.09 | -$0.31 | -$0.62 | -$0.22 | -$1.23 | -$1.80 | -$6.37 | -$2.90 |
| Diluted shares | 78.5M | 81.1M | 82.4M | 48.5M | 44.1M | 29.1M | 14.8M | 14.7M | 13.1M | 10.1M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.68M | $19.76M | $23.63M | $17.11M | $38.98M | $18.27M | $17.79M | $37.81M | $51.16M | $63.28M |
| Receivables | $8.84M | $2.91M | $5.27M | $4.59M | $3.44M | $2.00M | $4.70M | $4.73M | $1.72M | $693.0K |
| Inventory | $25.73M | $21.24M | $19.05M | $16.80M | $17.95M | $13.08M | $8.15M | $8.57M | $7.83M | $5.25M |
| Current assets | $66.67M | $60.08M | $69.93M | $44.88M | $61.67M | $55.72M | $32.48M | $52.98M | $62.65M | $71.87M |
| Total assets | $82.35M | $73.42M | $84.43M | $55.79M | $73.67M | $67.93M | $45.39M | $61.13M | $72.21M | $82.25M |
| Current liabilities | $26.52M | $25.62M | $45.53M | $32.43M | $33.18M | $86.47M | $40.17M | $25.35M | $22.75M | $66.21M |
| Total liabilities | $34.12M | $30.21M | $50.87M | $66.43M | $79.70M | $94.97M | $115.71M | $114.01M | $101.67M | $92.20M |
| Shareholders' equity | $48.23M | $43.21M | $33.57M | -$10.64M | -$6.04M | -$27.04M | -$70.32M | -$52.88M | -$29.46M | -$9.96M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.99M | $8.67M | -$1.32M | -$25.00M | -$10.29M | -$26.11M | -$19.36M | -$7.74M | -$9.99M | -$32.10M |
| Capital expenditures | $1.64M | $1.28M | $1.15M | $628.0K | $1.46M | $655.0K | $627.0K | $686.0K | $971.0K | $849.0K |
| Free cash flow | -$13.63M | $7.39M | -$2.47M | -$25.63M | -$11.74M | -$26.76M | -$19.98M | -$8.43M | -$10.96M | -$32.95M |
| Investing cash flow | -$2.37M | $4.22M | -$16.71M | -$5.04M | $18.92M | -$19.95M | -$883.0K | -$591.0K | -$1.12M | -$967.0K |
| Financing cash flow | $9.33M | -$16.79M | $24.67M | $8.24M | $12.08M | $46.47M | $0 | -$4.75M | -$1.42M | $19.70M |
| Stock-based compensation | $2.30M | $3.25M | $3.45M | $2.08M | $2.38M | $3.13M | $835.0K | $514.0K | $337.0K | $988.0K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -1.2% | -18.5% | 37.5% | 24.2% | -39.0% | 15.0% | 59.7% | 62.4% | 129.1% | 110.8% |
| Net income growth, YoY | - | -64.7% | - | - | - | - | - | - | - | - |
| EPS growth, YoY | - | -55.6% | - | - | - | - | - | - | - | - |
| Gross margin | 48.8% | 54.5% | 64.9% | 58.9% | 57.4% | 82.7% | 80.1% | 72.8% | 19.0% | 8.7% |
| Operating margin | -10.4% | 7.3% | 16.0% | -27.3% | -53.4% | 4.3% | -19.6% | -56.4% | -163.8% | -360.5% |
| Net margin | -12.5% | 5.5% | 12.7% | -31.3% | -71.9% | -10.4% | -33.4% | -77.3% | -395.9% | -319.2% |
| Free cash flow margin | -25.8% | 13.8% | -3.8% | -53.8% | -30.6% | -42.5% | -36.5% | -24.6% | -52.0% | -358.2% |
| Return on equity | -13.7% | 6.8% | 24.8% | - | - | - | - | - | - | - |
| Return on assets | -8.0% | 4.0% | 9.8% | -26.8% | -37.4% | -9.6% | -40.3% | -43.3% | -115.5% | -35.7% |
| Current ratio | 2.51 | 2.34 | 1.54 | 1.38 | 1.86 | 0.64 | 0.81 | 2.09 | 2.75 | 1.09 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.90M | $33.75M | $9.12M | $17.85M | $15.66M | $10.11M | $18.22M | $17.96M | $13.47M | $3.75M | $10.49M | $10.35M |
| Cost of revenue | $7.76M | $4.13M | $4.62M | $8.32M | $5.87M | $8.18M | $3.89M | $8.38M | $9.46M | $2.60M | $8.86M | $4.89M |
| Gross profit | $12.13M | $29.62M | $4.50M | $9.53M | $9.79M | $1.93M | $14.33M | $9.58M | $4.02M | $1.15M | $1.63M | $5.45M |
| Research and development | $4.35M | $5.43M | $5.63M | $4.47M | $5.99M | $3.48M | $4.12M | $3.00M | $2.96M | $2.89M | $3.10M | $3.67M |
| Selling, general and admin | $3.11M | $3.05M | $3.53M | $2.93M | $2.62M | $2.60M | $3.00M | $2.60M | $3.48M | $3.12M | $4.14M | $3.67M |
| Operating income | $4.67M | $21.15M | -$4.66M | $2.13M | $1.17M | -$4.14M | $7.21M | $3.99M | -$2.43M | -$4.86M | -$5.62M | -$1.89M |
| Pre-tax income | $4.86M | $21.14M | -$4.78M | $2.24M | $661.0K | -$3.73M | $7.32M | $3.84M | -$2.27M | -$4.73M | -$6.43M | -$1.72M |
| Income tax | $1.08M | $2.82M | $728.0K | -$116.0K | $497.0K | -$113.0K | $822.0K | $607.0K | -$69.0K | -$138.0K | -$382.0K | $133.0K |
| Net income | $3.78M | $18.32M | -$5.50M | $2.35M | $164.0K | -$3.62M | $6.49M | $3.24M | -$2.20M | -$4.59M | -$6.04M | -$1.85M |
| EPS, basic | $0.05 | $0.23 | -$0.06 | $0.03 | $0.00 | -$0.05 | $0.09 | $0.04 | -$0.03 | -$0.06 | - | -$0.03 |
| EPS, diluted | $0.05 | $0.22 | -$0.06 | $0.03 | $0.00 | -$0.05 | $0.10 | $0.03 | -$0.03 | -$0.06 | - | -$0.04 |
| Diluted shares | 82.6M | 83.0M | - | 80.8M | 81.3M | 76.6M | - | 81.2M | 73.3M | 73.0M | - | 83.8M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $27.42M | $41.00M | $14.68M | $13.65M | $17.89M | $19.46M | $19.76M | $27.41M | $23.40M | $27.21M | $23.63M | $20.41M |
| Receivables | $16.50M | $2.94M | $8.84M | $14.43M | $9.44M | $4.67M | $2.91M | $2.19M | $10.13M | $3.76M | $5.27M | $8.94M |
| Inventory | $32.29M | $30.47M | $25.73M | $21.25M | $21.13M | $19.51M | $21.24M | $17.20M | $20.72M | $22.35M | $19.05M | $21.58M |
| Current assets | $92.22M | $86.36M | $66.67M | $66.50M | $65.48M | $60.51M | $60.08M | $47.85M | $77.37M | $75.40M | $69.93M | $72.62M |
| Total assets | $110.34M | $102.34M | $82.35M | $82.26M | $78.49M | $73.89M | $73.42M | $61.56M | $91.54M | $89.83M | $84.43M | $87.57M |
| Current liabilities | $31.39M | $27.39M | $26.52M | $21.95M | $24.09M | $24.32M | $25.62M | $24.22M | $57.97M | $54.83M | $45.53M | $43.36M |
| Total liabilities | $38.93M | $35.11M | $34.12M | $29.36M | $28.58M | $28.68M | $30.21M | $29.13M | $62.96M | $60.04M | $50.87M | $49.32M |
| Shareholders' equity | $71.40M | $67.23M | $48.23M | $52.91M | $49.90M | $45.21M | $43.21M | $32.44M | $28.58M | $29.79M | $33.57M | $38.25M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.40M | $22.02M | $2.03M | -$3.73M | -$5.23M | -$5.06M | $3.99M | $4.11M | -$3.61M | $4.19M | $3.60M | -$6.89M |
| Capital expenditures | $593.0K | $761.0K | $403.0K | $498.0K | $431.0K | $306.0K | $425.0K | $87.0K | $172.0K | $598.0K | $250.0K | $447.0K |
| Free cash flow | -$10.99M | $21.26M | $1.63M | -$4.23M | -$5.66M | -$5.36M | $3.57M | $4.02M | -$3.78M | $3.59M | $3.35M | -$7.33M |
| Investing cash flow | -$3.63M | $4.22M | -$1.11M | -$504.0K | -$438.0K | -$312.0K | -$15.32M | $20.33M | -$180.0K | -$606.0K | -$342.0K | -$20.88M |
| Financing cash flow | $0 | $150.0K | $146.0K | $0 | $4.10M | $5.08M | $3.63M | - | - | - | $0 | $0 |
| Stock-based compensation | $398.0K | $532.0K | $732.0K | $598.0K | $427.0K | $540.0K | $654.0K | $620.0K | $998.0K | $981.0K | $1.37M | $1.10M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 27.1% | 233.7% | -49.9% | -0.6% | 16.2% | 169.8% | 73.7% | 73.6% | -61.6% | -60.9% | 21.7% | -27.1% |
| Net income growth, YoY | 2203.0% | - | - | -27.2% | - | - | - | - | - | - | - | - |
| EPS growth, YoY | - | - | - | 0.0% | - | - | - | - | - | - | - | - |
| Gross margin | 61.0% | 87.8% | 49.4% | 53.4% | 62.5% | 19.1% | 78.7% | 53.4% | 29.8% | 30.6% | 15.5% | 52.7% |
| Operating margin | 23.5% | 62.7% | -51.1% | 11.9% | 7.5% | -41.0% | 39.6% | 22.2% | -18.0% | -129.6% | -53.5% | -18.2% |
| Net margin | 19.0% | 54.3% | -60.3% | 13.2% | 1.0% | -35.8% | 35.6% | 18.0% | -16.4% | -122.6% | -57.6% | -17.9% |
| Free cash flow margin | -55.3% | 63.0% | 17.8% | -23.7% | -36.2% | -53.0% | 19.6% | 22.4% | -28.1% | 95.8% | 31.9% | -70.9% |
| Current ratio | 2.94 | 3.15 | 2.51 | 3.03 | 2.72 | 2.49 | 2.34 | 1.98 | 1.33 | 1.38 | 1.54 | 1.67 |
Source: XBRL data Protalix BioTherapeutics Inc. (DE) files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Mar 12, 2020.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PLX | $80.62M | +30.1% | $18.95M | 23.5% | $204.2M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |